American Portfolios Advisors Precision Biosciences Inc Transaction History

American Portfolios Advisors

  • $2.36 Trillion
  • Q3 2022

A detailed history of American Portfolios Advisors transactions in Precision Biosciences Inc stock. As of the latest transaction made, American Portfolios Advisors holds 33,929 shares of DTIL stock, worth $335,218. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,929
Holding current value
$335,218
% of portfolio
0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023
BUY
$1.22 - $2.06 $41,393 - $69,893
33,929 New
33,929 $44.1 Million
Q4 2021

Mar 21, 2023
SELL
$7.4 - $11.66 $27,750 - $43,725
-3,750 Reduced 11.05%
30,179 $223 Million
Q3 2021

Mar 22, 2023
SELL
$9.18 - $14.15 $32,130 - $49,525
-3,500 Reduced 10.32%
30,429 $351 Million
Q2 2021

Mar 22, 2023
SELL
$8.07 - $12.52 $28,245 - $43,820
-3,500 Reduced 10.32%
30,429 $381 Million
Q1 2021

Mar 22, 2023
SELL
$8.57 - $15.79 $32,137 - $59,212
-3,750 Reduced 11.05%
30,179 $312 Million
Q4 2020

Mar 22, 2023
SELL
$5.98 - $12.47 $22,425 - $46,762
-3,750 Reduced 11.05%
30,179 $252 Million
Q3 2020

Mar 22, 2023
SELL
$4.65 - $8.73 $17,437 - $32,737
-3,750 Reduced 11.05%
30,179 $186 Million
Q2 2020

Mar 24, 2023
SELL
$4.66 - $8.7 $23,300 - $43,500
-5,000 Reduced 14.21%
30,179 $251 Million
Q1 2020

Mar 24, 2023
BUY
$5.05 - $15.01 $6,312 - $18,762
1,250 Added 3.68%
35,179 $212 Million
Q4 2019

Mar 24, 2023
BUY
$6.32 - $19.66 $39,500 - $122,875
6,250 Added 18.42%
40,179 $558 Million

Others Institutions Holding DTIL

# of Institutions
7
Shares Held
2.56M
Call Options Held
0
Put Options Held
0
View Full List

About PRECISION BIOSCIENCES INC

DTIL Quotes by TradingView
  • Ticker DTIL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 110,818,000
  • Market Cap $1.09B
  • Description
  • Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...
More about DTIL
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email